Ulcerative Colitis (APD334-005)

The purpose of this extension study is to find out more about the safety and efficacy of APD334 for the treatment of moderately to severely active ulcerative colitis.  APD334 is an experimental drug which has not yet been approved by Health Authorities in any country of the world for the treatment of moderately or severely active ulcerative colitis (condition such as yours).

APD334 is being investigated to treat so-called autoimmune diseases, specifically inflammatory bowel diseases such as ulcerative colitis.  In autoimmune diseases, your immune system attacks its own tissues for some unknown reason. A group of white blood cells called lymphocytes plays a crucial role in this immune reaction. APD334 is a medication taken by mouth (tablet or capsule) that belongs to a group of drugs called S1P receptor agonists and works by reducing the number of lymphocytes in blood and therefore reducing the inflammation in the gut in participants with moderately to severely active ulcerative colitis.

Register Today!

Trial Information

Start DateAugust 2016
End DateTBD
Trial Duration42 weeks
Number of Visits13-15
Lead CRCMarija Bernstein

For additional information
on this trial contact: